Dupilumab benefits in kids with asthma hold out to 52 weeks
Dupilumab significantly continues to improve lung function — including measures of the large and small airways — out to 52 weeks in children with uncontrolled, moderate-to-severe asthma, according to 52-week data of the LIBERTY ASTHMA VOYAGE trial.